SNTA is a good example how to make money from the current situation. big pharma co's will stop spending 1B to dev drug from pre clinical till launch, they will buy them at 800M. SNAT will be bought by GSK, MRK, PFE or SNY. its a 600M drug in sales, so its 1.5B M&A within one year if the KRAS or the ALK for lung is working - we will see a nice run.
--->>if the KRAS or the ALK for lung is working<<---
You are missing the point of the data - the LDH group was actually the strongest group (a good chance it was 'stat sig' - as in under 0.05) and more of a value driver at this point than ALK. Certainly more so than mKRAS.
I believe, for lung cancer, it's all of the above, and possibly all-adeno as well. (Its much larger sample size compensates for the less spectacular results, so it could end up being statistically significant too.)
But lung cancer is just the tip of the iceberg. Most of the 20 trials for ganetespib are for other types of cancer.
And the fact that ganetestib can attack a dozen or more types of cancer SIMULTANEOUSLY is huge.
For annual sales, I'm envisioning a medium sized 10-digit number, and this may be conservative.